Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10848274 | 0.98 | CA1 (0.67) | CA1CA12CA2CA9GAA | |
| SCHEMBL16641986 | 0.84 | CA1 (0.64) | CA1CA12CA2CA9GAA | |
| SCHEMBL16641981 | 0.84 | CA12 (0.63) | CA1CA12CA2CA9GAA | |
| SCHEMBL16645384 | 0.83 | CA1 (0.52) | CA1CA12CA2CA9GAA | |
| SCHEMBL11764387 | 0.83 | CA12 (0.62) | CA1CA12CA2CA9GAA | |
| SCHEMBL15367450 | 0.81 | LMNA (0.47) | CA1CA12CA2CA9ALB | |
| SCHEMBL16645393 | 0.80 | CA12 (0.59) | CA1CA12CA2CA9GAA | |
| SCHEMBL16645403 | 0.80 | CYP2C9 (0.61) | CA1CA12CA2CA9GAA | |
| SCHEMBL16641984 | 0.79 | ALB (0.61) | CA1CA12CA2CA9GAA | |
| SCHEMBL10848159 | 0.79 | CA12 (0.64) | CA1CA12CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105324-A1 | COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-20150105324-A1 | COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-RE41549-E1 | Dyes for keratin fibers, the dyes containing n-benzyl-p-phenylenediamine derivatives and novel n-benzyl-p-phenylenediamine derivatives | WELLA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| EP-1226107-B1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1493731-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and these derivatives | Wella Aktiengesellschaft (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-6689174-B2 | FOR OXIDATIVELY DYEING HUMAN HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-02-10 | — | — | US | disclosed |
| US-20020166181-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and novel n-benzyl-p-phenylenediamine-derivatives | CHASSOT LAURENT (CH) | 2002-11-14 | — | — | US | disclosed |
| EP-1226107-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | Wella Aktiengesellschaft (DE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002018318-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105324-A1 | COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES | GRIN2A, GRIN1, GRIN2C | CA1 455/4885CA12 1006/4885CA2 2163/4885 |
| US-20020166181-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and novel n-benzyl-p-phenylenediamine-derivatives | KRT18, KPNB1, VIM | CA1 2791/4885CA12 2012/4885CA2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.